Abstracts tagged "B cells"

Abstract Number: 746 • 2016 ACR/ARHP Annual Meeting
Discrepancy in Rituximab-Induced B-Cell Depletion in Peripheral Blood and the Kidney and Relationship with Clinical Response in Patients with Lupus Nephritis
Ruth J. Pepper¹, Venkat Reddy², Scott Henderson³ and Maria J. Leandro⁴, ¹UCL Centre for Nephrology, Royal Free Hospital, London, United Kingdom, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³UCL Centre for Nephrology, University College London, London, United Kingdom, ⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Patients with lupus nephritis (LN) achieve variable clinical response following Rituximab (RTX) based B-cell depletion therapy, with rituximab treatment aiming to decrease the use…
Abstract Number: 1449 • 2016 ACR/ARHP Annual Meeting
The Efficiency of the Regulation of Ca2+ Entry through Calcium Release-Activated Calcium Channel in the Treatment of Rheumatoid Arthritis
Shuang Liu¹, Hitoshi Hasegawa², Takeshi Kiyoi³, Tatsuya Sawasaki⁴ and Kazutaka Maeyama⁵, ¹Dept. Pharmacology,, Ehime University Graduate School of Medicine, Toon-shi, Japan, ²Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan, ³Bioscience, Integrated Center for Sciences, Ehime University, Ehime, Japan, ⁴Division of Cell-Free Sciences, Proteo-Science Center, Ehime University, Matsuyama, Japan, ⁵Department of Pharmacology, Informational Biomedicine, Ehime University Graduate School of Medicine, Toon-shi, Ehime, Japan
Background/Purpose: The regulation of Ca2+ entry by targeting a store-operated calcium release-activated channel (CRAC), known as ORAI, has shown benefits in the treatment of rheumatoid…
Abstract Number: 2117 • 2016 ACR/ARHP Annual Meeting
B Cell Phenotype and in Vitro Function in Patients with Rheumatoid Arthritis Developing Low Serum Immunoglobulins after Multiple Cycles of Rituximab
Geraldine Cambridge¹, Rita A. Moura², Venkat Reddy³ and Maria J. Leandro¹, ¹Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ²Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Repeat treatment with rituximab (RTX) predisposes some patients with rheumatoid arthritis (RA) to develop low levels of serum immunoglobulins (Igs). Understanding B cell function…
Abstract Number: 762 • 2016 ACR/ARHP Annual Meeting
Pragmatic Treatment of Patients with Systemic Lupus Erythematosus with Rituximab: Long-Term Effects on Serum Immunoglobulins
Venkat Reddy¹, Lina Martínez-Estupiñán², David A. Isenberg³, Maria J. Leandro³ and Geraldine Cambridge³, ¹Rheumatology, University College Hospital, London, United Kingdom, ²Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: B cell depletion therapy based on rituximab is a therapeutic option for refractory disease in patients with Systemic Lupus Erythematosus (SLE). Hypogammaglobulinemia can be…
Abstract Number: 1456 • 2016 ACR/ARHP Annual Meeting
Identification of a Unique Population of B220hi B-Cells in Inflamed Lymph Nodes (Bin) As a Potential Biomarker of Arthritic Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Megan Forney¹, Richard Bell², Edward Schwarz³ and Homaira Rahimi⁴, ¹Orthopedics, University of Rochester, Rochester, NY, ²Pathology, University of Rochester, Rochester, NY, ³Orthopedeatrics, University of Rochester, Rochester, NY, ⁴Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Using the tumor necrosis factor transgenic (TNF-Tg) mouse model of rheumatoid arthritis (RA), we have shown that during progression of knee synovitis, popliteal lymph…
Abstract Number: 2430 • 2016 ACR/ARHP Annual Meeting
Mutations in the Tyrosine-Protein Kinase Lyn Cause an Early-Onset Neutrophilic Vasculitis Syndrome
Adriana Almeida de Jesus¹, Gina A. Montealegre¹, Helen Freeman², Neil Martin³, Ebun Omoyinmi⁴, Bernadette Marrero¹, Katherine R. Calvo⁵, Chyi-Chia Richard Lee⁶, April D. Brundidge⁷, David Kleiner⁸, Stephen Hewitt⁸, Dawn C. Chapelle⁷, Yan Huang¹, Nirali Shah⁸, Stephen Brooks⁷, Eric Meffre⁹, Paul Brogan¹⁰, Hyesun Kuehn¹¹, Sergio Rosenzweig¹², Melinda Merchant⁸, Zuoming Deng⁷, Susan Moir¹³ and Raphaela Goldbach-Mansky¹⁴, ¹National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²Raigmore Hospital, Inverness, United Kingdom, ³Royal Hospital for Children, Glasgow, United Kingdom, ⁴University College London Institute of Child Health, London, United Kingdom, ⁵Department of Laboratory Medicine, Hematology Section, National Institutes of Health Clinical Center, Bethesda, MD, ⁶Dermatopathology Section, Laboratory of Pathology, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, ⁷NIAMS/NIH, Bethesda, MD, ⁸National Cancer Institute, NIH, Bethesda, MD, ⁹Department of Immunobiology, Yale University School of Medicine, New Haven, CT, ¹⁰UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ¹¹Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, ¹²Department of Laboratory Medicine/NIH, Bethesda, MD, ¹³National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ¹⁴Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: Tyrosine-protein kinase Lyn is a Src-family tyrosine kinase expressed by hematopoietic and non-hematopoietic cell types. Phosphorylation of a tyrosine residue at position 508 renders…
Abstract Number: 781 • 2016 ACR/ARHP Annual Meeting
The Use of Rituximab in Newly Diagnosed Systemic Lupus Erythematosus Patients: Long Term Steroid Saving Capacity and Clinical Effectiveness
Borja del Carmelo Gracia Tello Sr.¹, David A. Isenberg² and Amara Ezeonyeji³, ¹Internal Medicina, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Zaragoza, Spain, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology, University College of London Hospital, London, London, United Kingdom
Background/Purpose: To assess the long term steroid saving capacity and clinical effectiveness of B-cell depletion therapy (BCDT) in newly diagnosed SLE patients. Methods: Sixteen female…
Abstract Number: 1610 • 2016 ACR/ARHP Annual Meeting
Safety, Tolerability, and Dose-Dependent Inhibition of T-Cell-Dependent Antibody Response with MEDI4920, a Novel, Engineered CD40L Antagonist: Results of a Single-Ascending Dose Study in Healthy Volunteers
Marius Albulescu¹, Jim Bush², Firas Almazedi², Ethan Grant³, Alex Godwood¹, Robert Miday⁴, Krista Arbaugh⁴, Lisa H. Butler¹, Michele Gunsior⁴, Jing Li⁵ and David Howe¹, ¹MedImmune, Cambridge, United Kingdom, ²Covance Clinical Research Unit, Leeds, United Kingdom, ³Translational Medicine, MedImmune, Gaithersburg, MD, ⁴MedImmune, Gaithersburg, MD, ⁵MedImmune, Mountain View, CA
Background/Purpose: The CD40L/CD40 co-stimulatory pathway is important for T-cell-dependent antibody production. Previous clinical programs with intact monoclonal antibodies against CD40L have been discontinued due to…
Abstract Number: 2608 • 2016 ACR/ARHP Annual Meeting
Anti-CCP Antibody Titers Decrease with Altered B-Cell Subpopulation in RA Patients Treated with Tocilizumab
Atsushi Noguchi^1,2, Shinsuke Yasuda¹, Ryo Hisada¹, Kazumasa Ohmura¹, Sanae Shimamura¹, Yuka Shimizu¹, Masaru Kato¹, Kenji Oku¹, Toshiyuki Bohgaki¹, Olga Amengual¹, Tetsuya Horita¹, Miho Suzuki³, Yoshihiro Matsumoto⁴ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Product research department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ⁴Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Consecutive RA patients who initiated treatment with TCZ between December 2013 and September 2015 were enrolled in our prospective study. All patients met 2010…
Abstract Number: 783 • 2016 ACR/ARHP Annual Meeting
Review of SLE Cohort to Identify Predictors of Response to B Cell Depletion in Patients with Active SLE
Pedro Mota¹, Ashleigh Hennessey², Ada Ferenkeh-Koroma² and David A. Isenberg², ¹Internal Medicine, Hospital da Luz, Lisbon, Portugal, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: The use of Rituximab (RTX) has been documented via published cohort data from over 20 sites worldwide (1,2) demonstrating its useful role in the…
Abstract Number: 1650 • 2016 ACR/ARHP Annual Meeting
Treatment with Tofacitinib Inhibits Human Naive B Lymphocyte Development and Function in Vitro
Jens Thiel¹, Nils Venhoff², Raquel Lorenzetti³, Bettina Bannert¹, Reinhard Voll⁴, Diego Kyburz⁵ and Marta Rizzi¹, ¹Department of Internal Medicine, Clinic for Rheumatology and Clinical Immunology, Freiburg, Germany, ²Department of Internal Medicine, Clinic for Rheumatology and Clincal Immunology, Freiburg, Germany, ³Department of Internal Medicine, Clinic for Rheumatology and Clinical Immunology, 79106, Germany, ⁴Dpt. Rheumatology & Clinical Immunology and Centre for Chronic Immunodeficiency, University Hospital Freiburg, University Medical Center, University of Freiburg, Freiburg, Germany, ⁵Department of Biomedicine, Experimental Rheumatology, University of Basel, 4051 Basel, Switzerland
Background/Purpose: B cells are pivotal to the pathogenesis of many autoimmune diseases including rheumatoid arthritis (RA). Tofacitinib, a JAK inhibitor, is effective and safe in…
Abstract Number: 2701 • 2016 ACR/ARHP Annual Meeting
Increased Frequency of Regulatory CD19+CD24high Cd38high B Cells in Patients with Ankylosing Spondylitis (AS)
M. Belén Bautista-Caro¹, Eugenio De Miguel¹, Diana Peiteado¹, Chamaida Plasencia-Rodriguez¹, Alejandro Villalba¹, Amaya Puig-Kröger², Paloma Sanchez-Mateos³, Emilio Martín-Mola¹ and Maria Eugenia Miranda-Carus¹, ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain, ³Immunology, Hospital Gregorio Marañon, Madrid, Spain
Background/Purpose: CD19+CD24highCD38high B cells have been described to have a regulatory capacity and their frequency is altered in the peripheral blood of patients with various…
Abstract Number: 811 • 2016 ACR/ARHP Annual Meeting
Basophils Are Activated and Stimulate Both B Cells and Fibroblasts in Systemic Sclerosis
Benjamin Chaigne¹, Nicolas Dumoitier², Alexis Regent¹, Benjamin Terrier³, Jonathan London², Matthieu Groh¹, Nathalie Thieblemont⁴ and Luc Mouthon⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ³Internal Medicine, Cochin Hospital, Paris, France, ⁴Inserm U1016, Paris, France, ⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a rare multisystem connective tissue disease characterized by skin and internal organs fibrosis and vascular abnormalities, along with the presence…
Abstract Number: 1826 • 2016 ACR/ARHP Annual Meeting
STAT3 Phosphorylation Mediates the Stimulatory Effects of Interferon Alpha on B Cell Differentiation and Activation in SLE
Julie Ducreux¹, Floor Aleva², Aurelie Degroof³, Alina Ferster⁴, Andre van der Ven², Frank van de Veerdonk², Frédéric A. Houssiau¹ and Bernard R. Lauwerys¹, ¹Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ²Department of General Internal Medicine, Radboud University, Nijmegen, Netherlands, ³Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ⁴Service d'Onco-Hématologie, Hôpital Reine Fabiola, Brussels, Belgium
Background/Purpose: In our previous work, we reported a link between interferon alpha inhibition and decreased expression of B cell activation genes in ex vivo whole…
Abstract Number: 2712 • 2016 ACR/ARHP Annual Meeting
Inverse Correlation Between IL-10-Producing Bregs and IFN-Gamma-Producing NK Cells in Psoriatic Arthritis and Psoriasis
Athanasios Mavropoulos¹, Areti Varna¹, Christos Liaskos¹, Efterpi Zafiriou², Marianna Vlychou³, Christina Katsiari⁴, Dimitrios Bogdanos⁵ and Lazaros I. Sakkas⁶, ¹Department of Rheumatology, School of Health Sciences, University of Thessaly, Larissa, Greece, ²Dermatology, University of Thessaly, Larissa, Greece, ³Radiology, University of Thessaly, Larissa, Greece, ⁴Department of Rheumatology, University of Thessaly, Larrisa, Thessaly, Greece, ⁵Department of Rheumatology, University of Thessaly, Larissa, Greece, ⁶University, Athens, Greece
Background/Purpose: A recent study from our group has shown functional impairment and numerical decrease of transitional and memory IL-10-producing regulatory B cells (Bregs) in patients…

« Previous Page
1
…
7
8
9
10
11
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.